# OnCo record rejuv-paed-second-cancers (technology). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/technologies/rejuv-paed-second-cancers/>
  a schema:MedicalTherapy ;
  onco:kind "technology" ;
  schema:identifier "rejuv-paed-second-cancers" ;
  schema:name "Second cancers after childhood cancer: the risk by treatment, and why it is falling"@en ;
  schema:description "The largest late risk a childhood cancer survivor carries. Thirty years after diagnosis, 20.5 per cent of survivors treated in the 1970s and early 1980s had developed a subsequent neoplasm. The fifteen-year risk of a second malignancy has since fallen from 2.1 to 1.3 per cent across treatment decades, and the fall tracks the radiotherapy taken out."@en ;
  schema:url <https://onco.cc/technologies/rejuv-paed-second-cancers/> ;
  schema:dateModified "2026-10-02"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Cancer_survivor> ;
  schema:citation <https://doi.org/10.1093/jnci/djq238>, <https://doi.org/10.1001/jama.2017.0693>, <https://doi.org/10.1001/jamanetworkopen.2025.48715>, <https://doi.org/10.1016/j.ctrv.2017.11.005>, <https://doi.org/10.1007/s10654-018-0370-3> ;
  onco:status "established" ;
  onco:tag "rejuvenation", "survivorship", "paediatric", "late-effects", "evidence:strong" ;
  onco:related <https://onco.cc/trials/ccss/>, <https://onco.cc/collections/sjlife/>, <https://onco.cc/collections/ighg/>, <https://onco.cc/collections/pancaresurfup/>, <https://onco.cc/technologies/rejuv-age-frailty-and-late-effects/>, <https://onco.cc/ideas/idea-acc-tailored-second-cancer-screening/> ;
  onco:cancers <https://onco.cc/cancers/childhood-cancers/>, <https://onco.cc/cancers/hodgkin-lymphoma/>, <https://onco.cc/cancers/ewing-sarcoma/>, <https://onco.cc/cancers/retinoblastoma/>, <https://onco.cc/cancers/all-leukemia/>, <https://onco.cc/cancers/wilms-tumor/>, <https://onco.cc/cancers/medulloblastoma/>, <https://onco.cc/cancers/thyroid/> ;
  onco:sections <https://onco.cc/fronts/rejuvenation/>, <https://onco.cc/fronts/supportive-care/>, <https://onco.cc/fronts/early-detection/> ;
  onco:technologies <https://onco.cc/terms/second-cancers-after-radiotherapy/>, <https://onco.cc/technologies/rejuv-paed-breast-after-chest-radiotherapy/>, <https://onco.cc/technologies/rejuv-paed-cog-ltfu-guidelines/>, <https://onco.cc/terms/radiotherapy/>, <https://onco.cc/technologies/proton-therapy/>, <https://onco.cc/technologies/germline-testing/> ;
  onco:drugs <https://onco.cc/drugs/cyclophosphamide/>, <https://onco.cc/drugs/etoposide/>, <https://onco.cc/drugs/doxorubicin/> ;
  onco:terms <https://onco.cc/terms/late-effects/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-survivorship/>, <https://onco.cc/bottlenecks/b-overdiagnosis/>, <https://onco.cc/bottlenecks/b-hereditary-risk/> .